Head of U.S. Rare Disease
Kim Moran is Head of U.S. Rare Diseases, where she oversees the rare disease commercial organization in the U.S., preparing for future launches and building the strategy for our entry into multiple rare diseases. Kim’s career began in rare, working in myasthenia gravis, and she believes through our deep understanding of patients and their needs, we have a responsibility to take risks to deliver for them. Over her nearly 15 years at UCB, she’s seen the organization grow and evolve, giving us the opportunity to gain closer proximity to patients, understand their unmet needs, and deliver unique solutions, including through digital pathways.
Kim has served as a catalyst for change within UCB. She was part of the team who advocated for a Diversity, Equity, and Inclusion Council and a full-time U.S. Diversity Lead. She also led the U.S. organization in digital business transformation, UCB’s effort to amplify scientific innovation through digital, data, and technology in order to make a bigger impact on stakeholders and for patients. She is a member of the U.S. Leadership Team, and is passionate about leadership, employee engagement, and innovative thinking.
Most recently, Kim was Head of Insights to Impact at UCB, a role she originated leading a team across finance, strategy, and operations to leverage insights and align our resources to have the greatest impact for patients, learning from patient insights. Drawing on her training as a neuroscientist and ten years of pharma industry business experience, she is committed to ensuring UCB delivers maximum value to the patients we serve.
Kim previously served as Head of Neurology Strategy in the U.S. and Head, Epilepsy Portfolio Strategy & Evolution within the Seizure Freedom Patient Value Mission. She collaborated across the business unit to uncover patient and caregiver insights and translate them into product and program innovations that increase value to those suffering from seizure disorders and solidify UCB’s leadership position in epilepsy.
She also served as Mission Lead for brivaracetam (BRV) lifecycle and medical affairs, where she was responsible for developing both the medical affairs launch plan and the BRV lifecycle management plan. Before that she was Mission Lead for Neupro Restless Legs Syndrome (RLS) lifecycle management and pioneered an innovative platform that used increased awareness of comorbidities in RLS to drive changes in the prevailing treatment paradigms.
Kim holds an Executive Global MBA from INSEAD, a Ph.D. in neuroscience and physiology from New York University and a BS in biochemistry and molecular biology from Penn State University. She also held a predoctoral fellowship from the National Science Foundation at the New York University Sackler Institute of Biomedical Sciences where she led research on brain imaging in Parkinson’s disease and the electrophysiology of synaptic vesicle proteins. She is author of nine published articles relating to neurology and more than 40 posters and abstracts.
She started in the pharmaceutical industry as Regional Medical Liaison at Aspreva Pharmaceuticals where she provided pre-launch support to Cellcept (mycophenolate mofetil) in Lupus nephritis and Myasthenia Gravis.
Kim sits on the Board of Nile, AI, an epilepsy care management platform that serves as a digital extension between the healthcare provider and patients with the ultimate goal of shortening the path to optimal care. She was named a Healthcare Businesswomen’s Association (HBA) Rising Star, named 40 under 40 by Medical, Marketing & Media (MM&M), and was awarded a PM360 Pharma Choice Award. She is also a member of CHIEF, which celebrates the most powerful women in leadership.
She lives in Marietta, Georgia with her husband and two children.